Clinical Trials Logo
  1. Home
  2. Branch Retinal Vein Occlusion
  3. NCT02215109
  4. Details
NCT02215109 Clinical Trial

Retinal Vessel Diameter in Branch Retinal Vein Occlusion

Branch Retinal Vein Occlusion Clinical Trial

Official title:
Change of Retinal Vessel Diameter in Branch Retinal Vein Occlusion After Intravitreal Bevacizumab Injection

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT02215109
Other study ID # KNUHOPH2014-01
Secondary ID
Status Completed
Phase N/A
First received August 11, 2014
Last updated August 29, 2016
Start date April 2012
Est. completion date August 2016

Study information
Verified date August 2016
Source Kyungpook National University
Contact n/a
Is FDA regulated No
Health authority Korea: Institutional Review Board
Study type Observational

Clinical Trial Summary

The authors investigated the consecutive change of retinal vessel's diameter in affected eye and fellow eye of Branch Retinal Vein Occlusion.

Description:

Twenty five consecutive patients who had undergone intravitreal bevacizumab injection for Branch Retinal Vein Occlusion with macular edema were included in this study. All subjects were enrolled between April, 2012 and April, 2013 in the Department of Ophthalmology, Kyungpook National University Hospital.

Recruitment information / eligibility
Status Completed
Enrollment 25
Est. completion date August 2016
Est. primary completion date July 2016
Accepts healthy volunteers No
Gender Both
Age group 40 Years to 85 Years
Eligibility Inclusion Criteria:

- Best-corrected visual acuity less than 20/40

- Central subfield macular thickness (CSMT) 300 µm or greater on spectral-domain optical coherence tomography

Exclusion Criteria:

- Patients with recurrent BRVO

- History of previous treatments for BRVO including vitreoretinal surgery, intravitreal injection, subtenon injection or laser photocoagulation

- Patients with diabetes or dyslipidemia

- IOP = 22mmHg, treatment for glaucoma, a family history of glaucoma, or optic neuropathy

- High myopia (<-6 Diopters), high hyperopia (>6 Diopters) or a history of refractive surgeries

- Co-existing retinal disease other than BRVO

- Corneal diseases include ulcer, keratoconus and a history of corneal laceration

- Cataract and other media opacities resulting in visual impairment or poor fundus images

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

Locations
Country Name City State
Korea, Republic of Dong Ho Park Daegu Kyungsangpookdo

Sponsors (1)
Lead Sponsor Collaborator
Kyungpook National University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome
Type Measure Description Time frame Safety issue
Primary Unoccluded retinal vessel diameter of Branch Retinal Vein Occlusion To evaluate the change of unoccluded retinal vessel diameter in affected eye of Branch Retinal Vein Occlusion and unaffected fellow eye. 0, 1, 3, and 6 months No
See also
  Status Clinical Trial Phase
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Active, not recruiting NCT04120311 - Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole Phase 1
Not yet recruiting NCT04601688 - Branch Retinal Vein Occlusion (BRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only. N/A
Completed NCT01968239 - Proof of Concept Study of Re-treatment in BRVO With Ranibizumab Guided by OCT Phase 2
Completed NCT00612261 - Sheathotomy vs. Intravitreal Triamcinolone for Branch Retinal Vein Occlusion N/A
Not yet recruiting NCT03637283 - Anti-VEGF Instead of Intraoperative Fan-shaped Photocoagulation in BRVO Combined With Vitreous Hemorrhage N/A
Completed NCT01976338 - Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO) Phase 3
Completed NCT01471691 - Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab Phase 1/Phase 2
Completed NCT01247220 - REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study Phase 2
Terminated NCT00642226 - Combined Vitrectomy and Triamcinolone in Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO) Phase 3
Terminated NCT05127525 - EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN) Phase 3
Completed NCT01599650 - Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Phase 3
Active, not recruiting NCT04120636 - Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole Phase 1
Recruiting NCT01975103 - Non-damaging Retinal Laser Therapy With PASCAL Laser for Macular Diseases Phase 2
Recruiting NCT01348633 - Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye N/A
Completed NCT04740905 - A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion Phase 3
Recruiting NCT02527733 - Retinal Sensitivity in BRVO After Anti-VEGF Therapy Phase 4
Completed NCT01396057 - Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO) Phase 3
Terminated NCT03802630 - Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion Phase 3
Completed NCT02478515 - Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion Phase 4